Insurance, affordability, FDA approvals, access, health policy, and cost-related IBD news.
Page 1 of 5 · 215 articles
Subtopics
Perceived stigma may affect how Black people with IBD view their care and whether they stick with medications, which can influence disease management and outcomes. Understanding these links can point to targets for...
If you have moderate–severe ulcerative colitis, this study suggests that typical phase III trials may exclude more than half of patients seen in specialty clinics, which can make trial results less representative of...
Early-onset IBD affects children worldwide and the commentary highlights that although deaths are declining, more children are living with IBD and social inequalities are widening — issues that can affect access to care,...
Faster, more accurate chart abstraction could speed IBD research and quality monitoring while reducing reviewer workload and errors, which may help registries and studies that rely on manually curated EHR data.
This note highlights a local center that offers comprehensive IBD care and raises awareness about IBD—useful if you or a family member are seeking specialized multidisciplinary treatment or information.
Insurance changes and rising premiums can force people with Crohn’s disease to skip or lose access to expensive biologic medications and routine care, which patients in the article say led to loss of treatment options...
Improving accuracy of IBD case identification in EMRs can make research and registries more reliable, reduce misclassification, and help ensure studies and quality programs use the right patient groups.
Rising IBD prevalence across Asia means more people will need diagnosis, long-term care, and health-system resources; patterns differ by country and by Crohn's disease versus ulcerative colitis, which affects planning...
An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.
Using TDM to optimize vedolizumab could improve outcomes but may raise treatment costs; patients and clinicians should know cost-effectiveness depends heavily on drug price and local healthcare thresholds.
The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.
Population estimates help patients understand how common IBD is and show that ulcerative colitis is more common than Crohn’s in this survey. Knowing prevalence and who is more likely to be diagnosed can help people feel...
This update is important because tofacitinib is a JAK inhibitor approved for adults with moderately to severely active ulcerative colitis after inadequate response to TNF blockers, and the label includes major safety...
This affects Crohn’s disease research funding and future drug-development pathways: a major pharmaceutical partner ended a collaboration that had aimed to discover T‑cell targets for Crohn’s disease, which could slow or...
An FDA approval of an autoinjector for ustekinumab may make self‑injection easier and more convenient for people with Crohn’s disease or ulcerative colitis who use this biologic. Changes in delivery format can also...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
A simple home test for urinary oxalate and Ox/Crea ratio could make monitoring more practical than 24-hour urine collections, helping prevent stone recurrence and allowing earlier treatment adjustments for people at...
A company acquisition shifts R&D focus toward fibrosis and brings a Crohn’s‑targeted anti‑fibrotic (RXC008) into a new corporate owner, which could influence development speed and resources for therapies aimed at...
The paper reports that hospitalized people with IBD have a higher risk of heparin-induced thrombocytopenia (HIT) and that HIT is associated with worse outcomes (higher mortality, longer stays, higher costs, and more...
Children with IBD often wait years for medicines to be approved after adult approvals; this review shows many ongoing paediatric trials for biologics and small molecules that could improve treatment options.
Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...
Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...
Growth and new approvals for Skyrizi and Rinvoq may increase treatment options and influence which drugs gastroenterologists prescribe for Crohn’s disease and ulcerative colitis. Changes in approvals, dosing options, and...
This news matters because SL-325 targets the TL1A/DR3 pathway, a novel immune target being tested for Crohn’s disease and UC; early Phase 1 data suggest a tolerable profile and prolonged target blockade that could affect...
Early clinical data suggest SL-325 engages its target (TL1A) with a favorable safety signal, and a Phase 2b trial in Crohn’s disease is planned — meaning this could become a new treatment option in the future if later...
Cure8 could only read part of this source from PubMed Central, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Natalizumab, and Biosimilars.
Cure8 found this source from Alimentary pharmacology & therapeutics, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Access, cost, and policy. Open the original article for...
The review links avoidable IBD hospital admissions to gaps in access across the care pathway, pointing to specific service areas (timely flare care, specialist access, self-management support) that could be changed to...
This bibliometric analysis summaries recent Spanish research activity in IBD, showing where work is concentrated, the mix of clinical versus basic/translational studies, and gender representation in scientific...
Virtual care reduced long-distance travel for IBD patients in remote Ontario, which both improves access to specialty care and appears to meaningfully lower travel-related CO2 emissions. Patients and clinics interested...
Handheld IUS could make noninvasive bowel assessment faster and more accessible for people with IBD, helping with triage and short-term monitoring without immediately resorting to endoscopy or advanced imaging.
The analysis suggests that placebo arms in Phase 3 IBD trials are associated with higher rates of serious events, mainly disease exacerbations; this matters because it raises ethical and safety concerns for people with...
If validated in clinical studies, extending the interval between subcutaneous vedolizumab doses could reduce injection frequency, costs, and treatment burden for some patients on maintenance therapy.
Immigrants with IBD reported substantial barriers to care — language gaps, work-related limits on attending appointments, and cultural concerns — which can hinder disease management. Recognizing these issues can help...
Standardized CCPs aim to improve consistency and quality of IBD care nationwide; nationalizing 16 CCPs could help reduce regional variation and support clinicians and patients in Canada.
IOIBD’s consensus frameworks and educational programs shape how IBD is studied and treated worldwide — affecting trial design, treatment goals, patient-reported outcome measures, and clinical guidance that patients and...
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab...
Surgical approach to creating an IPAA (j-pouch) affects timing and number of operations and recovery; trends toward more staged procedures may reflect increasing disease severity and preoperative treatment patterns that...
Shorter height at IBD diagnosis was more common in Hispanic/Latino children and those without private insurance, which may reflect inequities in timely diagnosis and access to nutrition and care—issues that can affect...
FDA drug-label updates change how a medicine should be used and monitored. For people with ulcerative colitis and other immune-mediated diseases, this label highlights safety risks and limits on combining tofacitinib...
This is an updated FDA drug label for tofacitinib, a JAK inhibitor that is approved for ulcerative colitis and other immune conditions.
Based on the title and source metadata, this appears to be a market or business news related to Access, cost, and policy. The original article is from firstwordpharma.com.
If approved, a vedolizumab biosimilar could increase treatment options and potentially lower costs or improve access to an established biologic used for moderate-to-severe Crohn’s disease and ulcerative colitis....
Regulatory review starts a formal approval process that could lead to a lower-cost biosimilar alternative to Entyvio (vedolizumab), potentially improving access to a biologic used in Crohn’s disease and ulcerative...
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
A vedolizumab biosimilar could increase access to an important biologic treatment for people with moderate‑to‑severe UC and Crohn’s disease by offering a potentially lower‑cost alternative. Regulatory review by the FDA...
Cure8 could only read part of this source from bignewsnetwork.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Access, cost, and policy.
People with both IBD and another immune-mediated disease (psoriatic disease) had more hospital admissions and higher inpatient costs over ten years in this population.
